Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF.


Journal Article

Eligible outpatients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) frequently do not receive target doses of HF medications. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) evaluated the effect of a practice-based performance improvement intervention on treatment of outpatients with LVEF ≤35%. Specific agent and dose were collected at baseline and 24 months for angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), β-blockers, and aldosterone antagonists. Changes in dosing over time were analyzed for each medication class. Data were available for 7605 patients. At baseline, target dose treatment rates were 36.1%, 20.5%, and 74.4%, respectively. Absolute and relative improvements of 9.8% and 47.7% ( P<.001) were achieved for β-blocker dosing at 24 months. The IMPROVE HF intervention was associated with significantly increased treatment of eligible patients with target doses of β-blockers but not ACE inhibitors/ARBs or aldosterone antagonists. Additional research to determine barriers to use of target doses of HF medications may be necessary.

Full Text

Duke Authors

Cited Authors

  • Gheorghiade, M; Albert, NM; Curtis, AB; Thomas Heywood, J; McBride, ML; Inge, PJ; Mehra, MR; O'Connor, CM; Reynolds, D; Walsh, MN; Yancy, CW; Fonarow, GC

Published Date

  • January 2012

Published In

Volume / Issue

  • 18 / 1

Start / End Page

  • 9 - 17

PubMed ID

  • 22277172

Pubmed Central ID

  • 22277172

Electronic International Standard Serial Number (EISSN)

  • 1751-7133

Digital Object Identifier (DOI)

  • 10.1111/j.1751-7133.2011.00250.x


  • eng

Conference Location

  • United States